Companies › Oncoinvent Solutions
1 active drug program in 1 registered trial: 1 Phase 2; Oncology; next expected readout Feb 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Radspherin® Alpha-emitting radionuclide (224Ra) delivered via intraperitoneal injection on biodegradab | – | Phase 2 | Peritoneal Carcinomatosis | Feb 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06504147 | Radspherin® | Phase 2 | Peritoneal Carcinomatosis | Oncology | Feb 2028 |
No annotated target.
–
NanoEcho Syncromune Galecto Biotech VSPharmTech BPGbio
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.